Despite SCOTUS, Myriad cashes in on BRCA; J&J on the hunt for deals in Boston;

 @FierceMedDev: St. Jude takes to Japan with MRI-safe pacer. Story | Follow @FierceMedDev

 @DamianFierce: For CROs big and small, you're only as good as your reputation. The view from  DIA 2013. Editor's corner | Follow @DamianFierce

 @MichaelGFierce: SEC hammers imaging company, CEO with fraud charges. Report | Follow @MichaelGFierce

> Despite the Supreme Court, Myriad Genetics ($MYGN) is still making money off its BRCA mutation tests, signing a companion diagnostics deal with Tesaro ($TSRO) for a cancer candidate. Article

> Johnson & Johnson ($JNJ) has opened the doors of its Boston Innovation Center, part of a worldwide effort to scout for new deals among early-stage life sciences companies. Story

> In a new study, BioVentrix's Revivent myocardial anchoring system helped heart failure patients sustain 39.6% improvement in heart function after one year. News

> Cepheid ($CPHD) won FDA clearance for its Xpert blood culture test to detect Methicillin-resistant Staphylococcus aureus (MRSA). More

> In new data on Natera's Panorama prenatal screening test, the diagnostic charted an average accuracy of 99.8% in detecting multiple sex chromosome abnormalities. Release

Biotech News

 @FierceBiotech: Big Data guru Atul Butte's NuMedii scores $3.5M VC round for 'digital' drug research. FierceBiotech IT story | Follow @FierceBiotech

 @JohnCFierce: Stanley Family Foundation spearheads a $21M round for Heptares - (GPCRs). News | Follow @JohnCFierce

 @RyanMFierce: J&J's pharma chairman lands 'more deals' in Boston innovation push. Report | Follow @RyanMFierce

> Celgene jumps into blood-cancer race with J&J, adding $818M MorphoSys deal. Report

> Reverse' DNA vaccine bursts into the spotlight with promising Type 1 diabetes data. News

> Genentech eyes 'breakthrough' cancer immunotherapies in pact with U.K. biotech. Story

> U.S. hands out retirement papers to chimps used for research. Article

Pharma News

 @FiercePharma: India suspends Actos on safety concerns. Two other (very old) drugs, too. Report | Follow @FiercePharma

 @EricPFierce: FDA goes from passive to aggressive on compounders. I wonder how long before certain Congressmen complain. More | Follow @EricPFierce

 @CarlyHFierce: Proxy fight heating up at Vivus... First Manhattan announces search for new CEO candidates. Yesterday's story | Follow @CarlyHFierce

> Pfizer, Amgen eye $1B deal for Russian biosimilars developer Biocad. Report

> Novo Nordisk steps away from now-controversial Paula Deen. Article

> Aspen feeds its global appetite with 2nd deal in a week. News

Pharma Manufacturing News

> Aspen, Merck deal includes API plants in U.S., Netherlands. Article

> Roche sets out strict expectations for contractors. Report

> Drugmakers more concerned with quality than price in picking CMOs. Item

> FDA spells out its expectations for crude heparin. More

Vaccines News

> Japan faces vaccine shortage in struggle to control rubella. Report

> ACIP rules on GSK, Novartis and Sanofi vaccines. Story

> Corruption alleged as Indian vaccine shortage continues. Item

> Type 1 diabetes vaccine impresses in early study. News

> Takeda tackling norovirus in bid to grow vaccine biz. Article